HUTCHMED (China) (HMDCF) Total Liabilities (2014 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Total Liabilities came in at $461.5 million in Q2 2026, down 13.59% year-over-year from $534.0 million in Q2 2025, and down 8.05% quarter-over-quarter from $501.8 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Total Liabilities (2014 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Total Liabilities for 13 consecutive years, with $461.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Liabilities fell 13.59% year-over-year to $461.5 million in Q2 2026; TTM through Jun 2026 was $461.5 million, a 13.59% decrease from a year earlier, with the FY2025 full-year figure at $501.8 million, changed N/A from the prior year.
- Total Liabilities was $461.5 million for Q2 2026 at HUTCHMED (China), down from $501.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $534.0 million in Q2 2025 and troughed at $342.5 million in Q2 2022.
- A 5-year average of $462.7 million and a median of $497.5 million in 2023 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities surged 45.26% in 2023 and slipped 13.59% in 2026, its largest moves.
- Over 5 years, Total Liabilities stood at $392.6 million in 2022, then advanced by 26.72% to $497.5 million in 2023, then increased by 2.29% to $508.8 million in 2024, then fell by 1.38% to $501.8 million in 2025, then declined by 8.05% to $461.5 million in 2026.
- The last three Total Liabilities figures came in at $461.5 million (Q2 2026), $501.8 million (Q4 2025), and $534.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 384.62 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 461.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 461.46 Mn |
| Dec 31, 2025 | 501.84 Mn |
| Jun 30, 2025 | 534.02 Mn |
| Jun 30, 2024 | 508.85 Mn |
| Jun 30, 2023 | 497.48 Mn |
| Dec 31, 2022 | 392.58 Mn |
| Jun 30, 2022 | 342.48 Mn |
| Dec 31, 2021 | 333.15 Mn |
| Sep 28, 2021 | -46.49 Mn |
| Jun 30, 2021 | 259.19 Mn |
| Mar 31, 2021 | 228.72 Mn |
| Dec 31, 2020 | 205.17 Mn |
| Jun 30, 2020 | 158.51 Mn |
| Dec 31, 2019 | 152.22 Mn |
| Sep 30, 2019 | 116.31 Mn |
| Jun 30, 2019 | 122.18 Mn |
| Mar 31, 2019 | 138.94 Mn |
| Dec 31, 2018 | 119.86 Mn |
| Sep 30, 2018 | -424.70 Mn |
| Jun 30, 2018 | 120.10 Mn |